Advertisement

Topics

Ipsen Company Profile

05:31 EST 23rd February 2019 | BioPortfolio

Ipsen is a global biopharmaceutical group with total sales in excess of 1 billion euros in 2009, and total worldwide staff of more than 4,400. Its strategy is based on fast growing specialty care drugs in oncology, endocrinology, neurology and hematology, and primary care drugs, which significantly contribute to research financing. This strategy is also supported by an active policy of partnerships. Ipsen’s specific Research & Development (R&D) centers and peptide & protein engineering platform give the Group a competitive edge. Nearly 900 people are dedicated to the discovery and development of innovative drugs for patient care. Nearly 900 people are dedicated to the discovery and development of innovative drugs for patient care. In 2009, R&D spend reached close to €200 million, representing more than 19% of total Group sales. Ipsen’s shares are traded on Segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150). Ipsen’s shares are eligible to the “Service de Règlement Différé” (“SRD”) and the Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit our website at www.ipsen.com.

Contact

Email: contact.investisseurs@ipsen.com


News Articles [81 Associated News Articles listed on BioPortfolio]

Ipsen to present new data from its oncology portfolio at the 2018 European Society for Medical ...

For further information :IpsenMediaIan Weatherhead, +44 (0) 1753 627733Vice President, Corporate External Communicationsian.weatherhead@ipsen.comorFanny Allaire, +33 (0) 1 58 33 ...

Ipsen appoints new general manager for the UK & Ireland

The French pharma company appointed a new general manager for its UK and Ireland office, Asad Mohsin Ali, who brings two decades of commercial experience and a bold vision for Ipsen’s global footpri...

Ipsen seeks candidates as it looks to spend over €1bn on pipeline growth

Ipsen is actively scouting candidates to boost its oncology, rare disease and neuroscience portfolio, said chief business officer Ivana Magovčević-Liebisch. The...Read More... The post Ipsen seeks ...

Exelixis and Ipsen start COSMIC-312 trial for advanced HCC

Exelixis and Ipsen have begun the Phase III COSMIC-312 trial of cabozantinib (cabometyx) in combination with atezolizumab (tecentriq) against sorafenib...Read More... The post Exelixis and Ipsen start...

With New HQ, Ipsen to Rapidly Expand North American Presence

With a patient-centric focus, Ipsen Biopharmaceuticals is on a mission to improve patients’ lives, leveraging its global reach and placing a strategic focus on external innovation.

First Patient Dosed in Ipsen and 3BP's Phase I/II Cancer Study

NewsIPN01087 is a compound that targets cancer cells in patients with advanced solid tumors which express the Neurotensin Receptor Subtype 1.

Exelixis, Ipsen's liver cancer drug approved in EU

The European Commission has approved Exelixis and Ipsen Pharma's Cabometyx, or cabozantinib, as a monotherapy in adult patien -More- 

STAT Plus: French pharma company Ipsen set to open Boston incubator this spring

The French pharmaceutical giant Ipsen is opening its new accelerator in Boston in April — and it’s already signed its first tenant.

Drugs and Medications [0 Results]

None

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Stability in GRN Inference.

Reconstructing a gene regulatory network from one or more sets of omics measurements has been a major task of computational biology in the last 20 years. Despite an overwhelming number of algorithms p...

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

Administration of GnRH Antagonist to Oocyte Donation Recipients

This prospective and randomized study was performed to evaluate whether the replacement of GnRH agonist by a GnRH antagonist in oocyte donation recipients during endometrial preparation h...

Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders

The purpose of this study is to compare ovulation induction using a flexible GnRH antagonist protocol and flare up GnRH agonist protocol in IVF patients with poor response to ovarian stimu...

Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients

The purpose of this study is to compare pregnancy rates and the occurrence of OHSS in PCOS patients who were treated with GnRH agonist and GnRH antagonist protocols ovarian stimulation dur...

Pharmaco-Economic Study of Cabozantinib in Renal Cell Carcinoma (RCC) Patients

In order to evaluate the cost-effectiveness (CE) of cabozantinib versus everolimus and axitinib for the adult aRCC patients who experienced the failure of prior VEGF-targeted therapy in Ta...

ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)

Renal cell carcinoma (RCC) is the 9th most common cancer in Australia, the 10th most common cancer in Western populations.~75% of kidney cancers are clear-cell renal cell carcinomas (ccRCC...

Companies [14 Associated Companies listed on BioPortfolio]

Ipsen N.A.

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2013. Ipsen’s ambition is to become a leader in specialty healthcare...

Ipsen S.A.

Ipsen is a global biopharmaceutical group, with sales exceeding 1 billion euros in 2009. The Group has total worldwide staff of more than 4,400 employees, of which nearly 900 cont...

The Fondation IPSEN

Established in 1983 under the aegis of the Fondation de France, the ambition of the Fondation IPSEN is to initiate a reflection about the major scientific issues of the forthcomin...

Ipsen

Ipsen is a global biopharmaceutical group with total sales in excess of 1 billion euros in 2009, and total worldwide staff of more than 4,400. Its strategy is based on fast growin...

Fondation Ipsen

Established in 1983 under the aegis of the Fondation de France, the mission of the Fondation Ipsen is to contribute to the development and dissemination of scientific knowledge. T...

More Information about "Ipsen" on BioPortfolio

We have published hundreds of Ipsen news stories on BioPortfolio along with dozens of Ipsen Clinical Trials and PubMed Articles about Ipsen for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ipsen Companies in our database. You can also find out about relevant Ipsen Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record